events & webinars

PRMT5 Inhibitors Targeting MTAP Deleted Cancers

PRMT5 symmetrically di-methylates arginine residues and is overexpressed in tumors
PRMT5 inhibition is effective in MTAP deleted cancers due to increased MTA concentrations, which sensitize the MTAP -/- cells to inhibition
PRMT5 inhibitors need to work cooperatively with MTA
Two targets identified with triple negative breast cancer

When:

Where:

Event Type

Event Organizer

Event Category

Instructions on how to participate here, whether it is to purchase tickets or register.

Gain visibility, build valuable relationships, and make a lasting impact. Partner with us to sponsor an event today